13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • WO39391

    Acronym: 

    WO39391

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Breast
    Trial Type Treatment
    Phase Phase III Tumour Stream Her 2 + Breast
    Age Range 18 years and older Cancer Stage All stages
    Sex Female Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Breast
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Female
    Molecular Target
    Tumour Stream Her 2 + Breast
    Cancer Stage All stages
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A phase III, multicentre, randomised, open-label study comparing atezolizumab (anti-Pd-L1 antibody) in combination with adjuvant anthracycline/ taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer

    Lay Summary

    Sponsor / Cooperative group

    Roche

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Sue Yeend syeend@adelaidecancercentre.com.au 08 8292 2240 Recruiting